Ravindra Mehta
Nephrology · San Diego, CANPI 1295818102
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $153,320 of the $183,589 with a category attached, or 83.5%. 16 manufacturers reported payments, led by AstraZeneca at 50.5% of the total. Reporting peaked in 2024 at $99,072 and has fallen 98.2% since, to $1,821 in 2025. Among nephrology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 110 payments — averaging $1668.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$93K
- Baxter Healthcare$29K
- GE HealthCare$14K
- Mallinckrodt Hospital Products Inc.$12K
- Sanofi US Services Inc.$11K
- Astute Medical, Inc.$10K
- plus $16K from 10 others
Across 1 payment — averaging $23,303 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Grifols Shared Services North America, Inc.$23K
What the payments were for
- Consulting fees$153,32084%
- Speaking & faculty fees$14,7508%
- Travel & lodging$6,6584%
- Food & beverage$3,0162%
- Education$5,8453%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 45 | $92,639 |
| Baxter Healthcare | 22 | $28,513 |
| GE HealthCare | 8 | $13,600 |
| Mallinckrodt Hospital Products Inc. | 6 | $12,140 |
| Sanofi US Services Inc. | 6 | $10,668 |
| Astute Medical, Inc. | 4 | $9,900 |
| Vifor Pharma, Inc. | 8 | $4,967 |
| Mallinckrodt Enterprises LLC | 3 | $4,121 |
| Abiomed | 1 | $2,750 |
| Vantive US Healthcare LLC | 1 | $1,400 |
| Covidien LP | 1 | $1,031 |
| Sumitomo Pharma Co., Ltd. | 1 | $675 |
| Intercept Pharmaceuticals, Inc. | 1 | $600 |
| Abbott | 1 | $400 |
| La Jolla Pharmaceutical Company | 1 | $168 |
| Biomerieux Inc | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ULTOMIRIS$29,433
- Renal - Acute$23,260
- NEPHROCHECK TEST$7,425
- Veltassa$4,736
- TERLIVAZ$3,710
- Impella$2,750
- Renal - PD$1,400
- VISIPAQUE$1,200
- Palindrome$1,031
- OCALIVA$600
- Afinion 2$400
How this compares
$183,589 in reported general payments places this provider in the 95th percentile of 1,341 nephrology providers in California.
Other nephrology in San Diego
- Ambarish AthavaleSan Diego$83K
- Juan QuevedoSan Diego$53K
- Anjay RastogiLos Angeles$2.2M
- Glenn ChertowStanford$2M
- Luis AlvarezPalo Alto$1.8M
- Jose MorfinSacramento$1M
- Rodolfo BatarseRancho Mirage$910K
- Vandana MathurWoodside$769K
- Yasir QaziOrange$618K
- Rafael VillicanaLoma Linda$610K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.